ClinicalTrials.Veeva

Find clinical trials for Leukemia in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes

Leukemia trials near New York, NY, USA:

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymph...

Active, not recruiting
Acute Lymphoblastic Leukemia, Pediatric
Drug: Erwinia asparaginase
Drug: MERCAPTOPURINE

Phase 3

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

New York, New York, United States and 8 other locations

the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute myeloid leukemia (AML)....

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: CC-90009
Drug: Azacitidine

Phase 1, Phase 2

Celgene
Celgene

Hackensack, New Jersey, United States and 13 other locations

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

New York, New York, United States and 51 other locations

in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...

Active, not recruiting
Leukemia
Drug: Dasatinib

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

New York, New York, United States and 173 other locations

in children with relapsed or refractory acute lymphoblastic leukemia or lymphoma (rALL) and assessing the combination dose of venetoclax com...

Enrolling
Refractory Acute Lymphoblastic Leukemia
Relapsed Acute Lymphoblastic Leukemia
Drug: Mercaptopurine
Drug: Etoposide

Phase 1, Phase 2

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital

New York, New York, United States and 1 other location

in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...

Enrolling
Refractory Acute Leukemia of Ambiguous Lineage
Acute Myeloid Leukemia, in Relapse
Drug: Methotrexate
Drug: Venetoclax

Phase 1

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital

Philadelphia, Pennsylvania, United States and 9 other locations

Phase 2 dose (RP2D) of SNDX-5613 in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: SNDX-5613
Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals
Syndax Pharmaceuticals

New York, New York, United States and 47 other locations

single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).The dose escalation (Part A) of the study will explor...

Enrolling
Leukemia, Myeloid
Drug: CC-96191

Phase 1

Celgene
Celgene

New York, New York, United States and 13 other locations

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia...

Active, not recruiting
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Drug: CC-90009

Phase 1

Celgene
Celgene

Hackensack, New Jersey, United States and 18 other locations

An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)...

Enrolling
T-cell Large Granular Lymphocytic Leukemia
Drug: ABC008

Phase 1, Phase 2

Abcuro

New York, New York, United States and 8 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems